VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

PHR.US

25.33

-0.94%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

PHR.US

25.33

-0.94%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

PHR.US

25.33

-0.94%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

PHR.US

25.33

-0.94%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

PHR.US

25.33

-0.94%↓

Search

Medtronic PLC

Uždarymo kaina

SektoriusSveikatos priežiūra

88.44 -1.53

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

88.2

Max

89.76

Pagrindiniai rodikliai

By Trading Economics

Pajamos

32M

1.3B

Pardavimai

-111M

8.3B

P/E

Sektoriaus vid.

27.479

73.239

Pelnas, tenkantis vienai akcijai

1.39

Dividendų pajamingumas

3.11

Pelno marža

15.798

Darbuotojai

95,000

EBITDA

-40M

2.4B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+7.28% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

3.11%

3.06%

Kitas uždarbis

2025-05-22

Kitas dividendų mokėjimo data

2025-04-11

Kita Ex Dividend data

2025-06-27

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-5B

116B

Ankstesnė atidarymo kaina

89.97

Ankstesnė uždarymo kaina

88.44

Naujienos nuotaikos

By Acuity

36%

64%

109 / 386 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Medtronic PLC Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-02-18 12:24; UTC

Uždarbis

Medtronic 3Q Revenue Rises on Strength in Cardiovascular, Neuroscience

2024-11-19 12:27; UTC

Uždarbis

Medtronic Narrows Fiscal Year Guidance as 2Q Tops Views

2025-02-27 10:30; UTC

Svarbiausios naujienos

Squeezed by Strong Dollar, Companies Try to Neutralize Currency Swings -- WSJ

2025-02-18 11:47; UTC

Uždarbis

Medtronic: Will Accelerate Top-, Bottom-Line Growth in 4Q >MDT

2025-02-18 11:46; UTC

Uždarbis

Medtronic Still Sees FY25 Organic Revenue Growth 4.75%-5% >MDT

2025-02-18 11:45; UTC

Uždarbis

Medtronic 3Q Adj EPS $1.39 >MDT

2025-02-18 11:45; UTC

Uždarbis

Medtronic 3Q Neuroscience Portfolio Rev $2.46B >MDT

2025-02-18 11:45; UTC

Uždarbis

Medtronic 3Q Net $1.29B >MDT

2025-02-18 11:45; UTC

Uždarbis

Medtronic 3Q Diabetes Rev $694M >MDT

2025-02-18 11:45; UTC

Uždarbis

Medtronic 3Q Medical Surgical Portfolio Rev $2.07B >MDT

2025-02-18 11:45; UTC

Uždarbis

Medtronic 3Q Cardiovascular Portfolio Rev $3.04B >MDT

2025-02-18 11:45; UTC

Uždarbis

Medtronic 3Q Organic Revenue Up 4.1% >MDT

2025-02-18 11:45; UTC

Uždarbis

Medtronic 3Q EPS $1.01 >MDT

2025-02-18 11:45; UTC

Uždarbis

Medtronic Sees FY Adj EPS $5.44-Adj EPS $5.50 >MDT

2025-02-18 11:45; UTC

Uždarbis

Medtronic 3Q Sales $8.29B >MDT

2025-02-18 10:01; UTC

Uždarbis
Karštos akcijos

Stocks to Watch Tuesday: Intel, Baidu, Constellation Brands -- WSJ

2025-01-21 19:15; UTC

Svarbiausios naujienos

Medtronic Hires CFO From Renault -- Update

2025-01-21 12:17; UTC

Svarbiausios naujienos

Medtronic Hires CFO From Renault

2024-11-19 12:12; UTC

Uždarbis

Medtronic Narrows FY Guidance as 2Q Tops Views

2024-11-19 11:46; UTC

Uždarbis

Medtronic Sees High-Single-Digit Adjusted EPS Growth in 2nd Half of FY25 >MDT

2024-11-19 11:46; UTC

Uždarbis

Medtronic Narrows FY25 Organic Rev Growth View to 4.75%-5% From 4.5%-5% >MDT

2024-11-19 11:45; UTC

Uždarbis

Medtronic 2Q Medical Surgical Portfolio Rev $2.13B >MDT

2024-11-19 11:45; UTC

Uždarbis

Medtronic 2Q Adj EPS $1.26 >MDT

2024-11-19 11:45; UTC

Uždarbis

Medtronic 2Q Diabetes Rev $686M >MDT

2024-11-19 11:45; UTC

Uždarbis

Medtronic 2Q Neuroscience Portfolio Rev $2.45B >MDT

2024-11-19 11:45; UTC

Uždarbis

Medtronic 2Q Net $1.27B >MDT

2024-11-19 11:45; UTC

Uždarbis

Medtronic 2Q Organic Revenue Up 5.0% >MDT

2024-11-19 11:45; UTC

Uždarbis

Medtronic 2Q Cardiovascular Portfolio Rev $3.1B >MDT

2024-11-19 11:45; UTC

Uždarbis

Medtronic Sees FY Adj EPS $5.44-Adj EPS $5.50 >MDT

2024-11-19 11:45; UTC

Uždarbis

Medtronic 2Q Sales $8.4B >MDT

Akcijų palyginimas

Kainos pokytis

Medtronic PLC Prognozė

Kainos tikslas

By TipRanks

7.28% į viršų

12 mėnesių prognozė

Vidutinis 96.4 USD  7.28%

Aukščiausias 109 USD

Žemiausias 85 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Medtronic PLC kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

19 ratings

9

Pirkti

9

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

88.02 / 90.29Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Weak Bullish Evidence

Rinkos nuotaikos

By Acuity

109 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.